Paper Publications

2023 – Recent Patents on Anti-Cancer Drug Discovery
Wiseman CL, Kharazi A, et al. Regression of Breast Cancer Metastases Following Treatment with Irradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer Cell Line: Intellectual Property and Immune Markers of Response. Recent Patents on Anti-Cancer Drug Discovery, 2023, 18, 224-240
2018 – Frontiers in Immunology
Lacher MD, and Bauer G, et al. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4 + T Lymphocytes. Frontiers in Immunology, 2018, Volume 9, Article 776
2010 – Proof of Concept Phase I Study (14 Patients)- The Open Breast Cancer Journal
Wiseman CL, Kharazi A. Phase I Study with SV-BR-1 Breast Cancer Cell Line Vaccine and GMCSF: Clinical Experience in 14 Patients; The Open Breast Cancer Journal, 2010, 2, 4-11
2006 – Clinical Regression – The Breast Journal
Wiseman CL, Kharazi A. Objective Clinical Regression of Metastatic Breast Cancer in Disparate Sites after Use of Whole-Cell Vaccine Genetically Modified to Release Sargramostim; Clinical Regression – The Breast Journal


Poster Publications

2023

SABCS
Updated survival and clinical data of Phase 2 Study of the Bria-IMT combination regimen; Presentation ID P03-05-12
Calfa C, Nangia C et al. Randomized Phase 2 of Bria-MT, an Allogenic Human Cell Line with Antigen Presenting Activity in Heavily Pretreated Metastatic Breast Cancer. Cancer Res. December 2023, Presentation ID P03-05-12
Presentation ID: PO2-13-06
Lopez-Lago M, Chang M et al. Analysis of Antibody Response to SV-BR-1-GM Therapeutic Vaccine in Breast Cancer Patients Using Human Protein Microarrays: Potential Correlations with Therapy Response. Cancer Res. December 5-9, 2023, Presentation ID: PO2-13-06
Presentation ID: PO1-20-12
Kuker R, Valdes-Albini F et al. CD8+ Tumor Infiltrating Lymphocytes Turn a Cold Tumor Hot in Metastatic Breast Cancer. Sylvester Comprehensive Cancer Center, Presentation ID: PO1-20-12
SITC
2023 SITC – Poster
Lopez-Lago M, Kesarwani P et al. Development and Mechanism of Action of a Novel Cellular Immunotherapeutic Platform for the Treatment of Advanced Solid Tumors .November 1-5, 2023
ASCO
2023 ASCO – Poster 1
Kasabwala DM, Cristofanilli M et al. Correlation of micronuclei formation in circulating stromal cells with their PD-L1 expression and predicts for poorer clinical outcomes in metastatic breast cancer. DOI 10.1200/JCO.2023.41.16_suppl.e14548
2023 ASCO – Poster 2
Gardner KP, Cristofanilli M et al. Sequential monitoring of tumor macrophage fusion cells in the circulation of metastatic breast cancer and their prognostic value. DOI 10.1200/JCO.2023.41.16_suppl.3054


AACR
2023 AACR – Poster 1 (Positive Data Demonstrating Survival and Clinical Benefits)
Chumsri S, Barve M, Nangia C, et al. Whole cell antigen presenting immune stimulating cells (Bria-IMT) for the treatment of metastatic breast cancer. Cancer Res. April 15, 2023;83(8 Supplement):CT143. doi:10.1158/1538-7445.AM2023-CT143
2023 AACR – Poster 2
Lopez-Lago MA, Bhardwaj V, Zheng X, et al. Engineering semi-allogeneic whole cancer vaccines with enhanced immunogenicity for the treatment of advanced solid tumors. Cancer Res. 2023;83(7_Supplement):685. doi:10.1158/1538-7445.AM2023-685
2023 AACR – Poster 3
Adams DL, Alpaugh RK et al. Tumor-Macrophage Fusion Cells detected in the circulation of metastatic breast cancer patients is prognostic for rapid progression and death. CreatvBio, April 14-19, 2023, Abstract 2310
2023 AACR – Poster 4
Kasabwala DM, Cristofanilli M et al. Micronuclei in Circulating Stromal Cells Correlated with PD-L1 Expression and Predicts Progression in Metastatic Breast Cancer; CreatvBio 2023, Abstract No. 6697


2022

SABCS
2022 SABCS – Combination Study Efficacy
Chumsri S, Williams WV et al. Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell Therapeutic Vaccine in Advanced Metastatic Breast Cancer; SABC 2022 Poster ID P3-07-12
2022 SABCS – CTCs/CAMLs Biomarker Tools
Adams DL, Chang M, et al. Decreases in Circulating Tumor Associated Cells Predict PFS and OS in a Pooled Analysis of Phase I Clinical Trials Using SV-BR-1-GM Therapy with or without Immune Check-Point Inhibitors in Metastatic Breast Cancer Patients. CreatvBio, December 6-10, 2022, Poster ID: P1-05-28
2022 SABCS – Enhancing Personalized Immunotherapy (Bria-OTS2.0)
Lopez-Lago M, Pachhal S et al. Turning tumor cells into antigen-presenting cells for cancer immunotherapy. December 7-10, 2022
SITC
2022 SITC – Poster
Lopez-Lago M, Del Priore G et al. An off-the-shelf personalized cellular approach to immunotherapy for the treatment of advanced solid tumors. SITC, November 8-12, 2022
AACR
2022 AACR Poster
Williams WV, Lacher MD et al. Toward a Personalized Off-the-Shelf Cellular Immunotherapy for Cancer. AACR, April 8-13, 2022
2022 AACR – Abstract
Williams WV, Lacher MD et al. Toward a personalized off-the-shelf cellular immunotherapy for cancer. Abstract 3557, AACR Journals 15 June 2022, Volume 82, Issue 12_Supplement; 10.1158/1538-7445.AM2022-3557


2021

SABCS
2021 SABCS – Poster
Williams WV, Dakhil SR et al. Overall Survival following treatment with a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer. San Antonio Breast Cancer Symposium December 7-10, 2021
AACR
2021 AACR Poster
Williams WV, Lacher MD et al. Predictors of response to a modified whole tumor cell immunotherapy in patients with advanced breast cancer from two phase I/IIa trials .AACR 2020 Abstract CT102
2021 Keystone Symposium
Williams WV, Lacher MD. Personalized off-the-shelf whole cell immunotherapy for cancer. Keystone Symposium 2021


2020

SABCS
2020 SABCS Poster
Williams W, Dakhil SR, Calfa CJ, et al. Breast cancer grade and clinical benefit in patients with advanced breast cancer treated with an engineered whole tumor cell-targeted immunotherapy alone or in combination with checkpoint inhibition. J Clin Oncol. 2020;38(15_suppl):3033-3033.
ASCO
2020 ASCO Poster
Williams, Shaker R. Dakhil; Breast cancer grade and clinical benefit in patients with advanced breast cancer treated with an engineered whole tumor cell-targeted immunotherapy alone or in combination with checkpoint inhibition; Abstract 97
2020 ASCO Abstract
William Williams, Shaker R. Dakhil; Breast cancer grade and clinical benefit in patients with advanced breast cancer treated with an engineered whole tumor cell-targeted immunotherapy alone or in combination with checkpoint inhibition; J Clin Oncol 38: 2020 (suppl; abstr 3033), DOI 10.1200/JCO.2020.38.15_suppl.3033, Abstract 3033, Poster 97
AACR
2020 AACR Poster
Sunkari V, Galeas J et al. Clinical and pharmacodynamic responses to a modified whole tumor cell immunotherapy in patients with advanced breast cancer from two phase I-IIa trials; AACR 2020 5588 / 21 (Virtual)
Other conferences
2020 – 3rd Annual Biologics World Nordic
2020 – SSO International Conference on Surgical Cancer Care™
PM Kemp Bohan, RC Chick; Results of a Phase I/IIa Trial of Combination Whole-Cell Targeted Immunotherapy Vaccine and Checkpoint Inhibitor in Treatment of Metastatic/Recurrent Breast Cancer; Cancer Vaccine Development Program
2020 – Mount Sinai’s Frontiers in Academic Pathology Symposium


2019

SABCS
2019 – SABCS Poster
Williams WV, Dakhil SR et al. Efficacy and safety of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer alone and in combination with immune checkpoint inhibitors
2019 – AACR Poster
Sunkari V, Graeve S et al. Development of a personalized off-the-shelf whole-cell immunotherapy for breast cancer; AACR 2019 #4998
2019 – 2nd Annual Next Gen Immuno-Oncology Congress
Williams WV. Breast Cancer Immunotherapy: Novel Combinations of Bria-IMT™ with Checkpoint Inhibitors, September 2019
2019 – Precision Breast Cancer Summit
Williams WV. Can Cancer Immunotherapy be both Personalized and Off-the-Shelf?; April 2019
2019 – Keystone Symposia Conference
Sunkari V, Graeve S et al. SV-BR-1-GM, a breast cancer cell line with features of dendritic cells, induces tumor regression in HLA matched Stage IV breast cancer patients; Keystone Symposium Conference January 20-24, 2019
2019 ASCO Abstract
Williams WV, Holmes JP et al. safety and efficacy of a phase l/lla trial (NCT03066947) of a modified whole tumor cell targeted immunotherapy in patients with advanced breath cancer; ASCO 2019, May 31- June 4 2019
2019 – ASCO-SITC Clinical Immuno-Oncology Symposium
Sunkari V, Williams WV et al. Targeted Tumor-Derived Cellular Immunotherapy in Advanced Breast Cancer Patients Induces Initial Immune Responses and Tumor Regression. SCO/SITC Meeting February 28 – March 1 2019


2018

SABCS
2018 SABCS Poster
Bhattacharya S, Holmes JP, Calfa C, et al. Initial safety and efficacy of a phase I/IIa trial of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer. Cancer Res. February 15, 2019;79(4_Supplement):P2–09–09. doi:10.1158/1538-7445.SABCS18-P2-09-09.
AACR
2018 AACR – Bria-IMT™ – Clinical Data
Holmes JP, Williams W, Peoples GE, et al. SV-BR-1-GM a whole-cell targeted immunotherapy for breast cancer: Preliminary clinical data. J Clin Oncol. 2018;36(15_suppl):e15165-e15165.
2018 AACR Poster – Bria-IMT™ – Mechanism of Action
2018 – CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference


2017


2016

SABCS
2016 SABCS Poster
Wiseman CL, Lacher M. A phase I/IIa study of the whole-cell vaccine BriaVax™ in metastatic or locally recurrent breast cancer patients (NCT00095862). Cancer Res. 2017;77(4_Supplement):OT3–01–06. doi:10.1158/1538-7445.SABCS16-OT3-01-06
AACR
2016 AACR Poster
Lacher MD, Wiseman CL, Wagner J. Molecular profile of a GM-CSF overexpressing breast cancer whole-cell vaccine with systemic anti-tumor activity. Cancer Res. July 15, 2016;76(14_Supplement):2369. doi:10.1158/1538-7445.AM2016-2369


2015

2015 – 7th Annual Immunotherapeutics & Immunomonitoring Conference
Wiseman CL, Kharazi AI. BriaVax Regressions in Metastatic Breast Cancer: Preliminary Results and Description of Pending Clinical Trial, 2015